Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
复制标题
DOI：
10.1086/510079
复制
发表时间：
2007-01-01
影响因子：
11.8
通讯作者：
Drusano, George L.
中科院分区：
文献类型：
--
作者：
Ambrose, Paul G.;Bhavnani, Sujata M.;Drusano, George L.
自20世纪30年代抗微生物化疗的现代时代到来以来，动物感染模型已经允许用于治疗实验诱导的感染的抗微生物剂的体内评价。今天，动物药代动力学-药效学（PK-PD）感染模型作为抗菌药物和剂量及给药间隔选择的临床前评估过程的基石，作为设定体外敏感性折点的决策支持，并最终用于评价体外耐药性的意义。在过去的15年里，大量的PK-PD数据来自感染患者的许多类别的抗菌药物。这些数据为确认从动物PK-PD感染模型中获得的知识提供了机会。
Since the advent of the modern era of antimicrobial chemotherapy in the 1930s, animal infection models have allowed for the in vivo evaluation of antimicrobial agents for the treatment of experimentally induced infection. Today, animal pharmacokinetic-pharmacodynamic (PK-PD) infection models serve as a cornerstone of the preclinical assessment process for antibacterial agents and dose and dosing interval selection, as decision support for setting in vitro susceptibility breakpoints, and, finally, for the evaluation of the meaning of in vitro resistance. Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models.